On Oct 18, major Wall Street analysts update their ratings for $Abbott Laboratories (ABT.US)$, with price targets ranging from $130 to $146.
BofA Securities analyst Travis Steed maintains with a buy rating, and maintains the target price at $133.
Citi analyst Joanne Wuensch maintains with a buy rating.
UBS analyst Danielle Antalffy maintains with a buy rating, and adjusts the target price from $143 to $146.
TD Cowen analyst Josh Jennings maintains with a buy rating, and maintains the target price at $130.
Mizuho Securities analyst Anthony Petrone maintains with a hold rating, and adjusts the target price from $115 to $130.
Furthermore, according to the comprehensive report, the opinions of $Abbott Laboratories (ABT.US)$'s main analysts recently are as follows:
Abbott's recent modest sales and EPS beat reinforces confidence in the company's capacity to maintain double-digit MedTech sales expansion for the foreseeable future and overall high single-digit sales growth. The sustainability of Abbott's MedTech business growth trajectory is thought to be undervalued, presenting Abbott as a top opportunity for high single-digit to low double-digit sales growth.
Following Q3 results, adjustments have been made to the outlook for Abbott, suggesting the company is in a good position to handle any competitive pressures from pulsed field ablation. Additionally, the potential for leadless pacing may contribute to an acceleration of cardiac rhythm management growth beyond 3%. Despite the strong position and solid operational execution, it is assessed that market expectations have been met and that the company's valuation is reasonable when compared to its peers.
Despite the company's momentum, there is an ongoing search for sustainable operating margin expansion beyond the period of Testing decline.
Abbott's third-quarter sales exceeded expectations, propelled by strong performance in MedTech and COVID-19 testing, while keeping its organic growth forecast for FY24 steady and slightly raising the midpoint of its EPS outlook. Despite concerns regarding valuation and ongoing litigation, there's a sense of optimism about Abbott's performance.
Abbott's management conveyed optimism regarding the company's forecast for continued high single-digit revenue growth and double-digit earnings expansion. The CEO indicated that a high single-digit revenue increase and 10% earnings per share growth are within reach as a fundamental expectation. The presence of multiple new offerings in the rapidly advancing Diabetes Care and Structural Heart sectors suggests that Abbott's entire medical Device collection is poised for superior growth within the MedTech industry.
Here are the latest investment ratings and price targets for $Abbott Laboratories (ABT.US)$ from 7 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美东时间10月18日，多家华尔街大行更新了$雅培 (ABT.US)$的评级，目标价介于130美元至146美元。
美银证券分析师Travis Steed维持买入评级，维持目标价133美元。
花旗分析师Joanne Wuensch维持买入评级。
瑞士银行分析师Danielle Antalffy维持买入评级，并将目标价从143美元上调至146美元。
TD Cowen分析师Josh Jennings维持买入评级，维持目标价130美元。
瑞穗证券分析师Anthony Petrone维持持有评级，并将目标价从115美元上调至130美元。
此外，综合报道，$雅培 (ABT.US)$近期主要分析师观点如下：
Abbott最近良好的销售和每股收益超过了市场预期，增强了人们对公司能够在可预见的未来保持两位数医疗科技销售增长和总体高位数的销售增长的信心。人们认为Abbott医疗科技业务增长轨迹的可持续性被低估，使Abbott成为高位数到低两位数销售增长的顶级机会。
在第三季度的业绩发布之后，对Abbott的展望进行了调整，表明公司在处理来自脉冲场消融的任何竞争压力方面处于良好位置。此外，无导线起搏的潜力可能有助于加速心脏节律管理增长超过3%。尽管处于强势地位且运营执行良好，但市场预期已得到满足，与同行相比，公司的估值被认为是合理的。
尽管公司势头强劲，但仍在努力寻求持续营业利润率的增长，超越测试业务下降的期间。
Abbott第三季度的销售超出预期，受益于医疗科技和COVID-19测试的强劲表现，同时保持其FY24的有机增长预测稳定，并略微调高了每股收益展望的中间部分。尽管存在对估值和持续诉讼的担忧，但人们对Abbott的表现抱有乐观态度。
Abbott管理层对公司持续高位数营业收入增长和两位数盈利扩张的预测表达了乐观态度。首席执行官指出，预计公司将实现高位数营业收入增长和10%的每股收益增长作为基本预期。在快速发展的糖尿病护理和结构性心脏领域推出了多款新产品，表明Abbott的整个医疗器械产品系列都处于医疗科技行业内卓越增长的有利位置。
以下为今日7位分析师对$雅培 (ABT.US)$的最新投资评级及目标价：
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
